Review

Diabetic Dermopathies as Predictive Markers of Cardiovascular and Renal Complications: A Narrative Review

Madalina Marinescu , Gina Eosefina Botnariu * , Dan Vâță * , Adriana-Ionela Patrascu , Doinița Temelie-Olinici , Mădălina Mocanu , Ioana Halip , Ioana Adriana Popescu , Dragoș Florin Gheuca-Solovastru , Laura Gheuca-Solovastru

Posted Date: 9 September 2025

doi: 10.20944/preprints202509.0808.v1

Keywords: diabetes mellitus; cutaneous manifestations; diabetic dermopathy; skin and diabetes; non-invasive markers; systemic complications

 doi:10.20944/preprints202509.0808.v1

Review

Diabetic Dermopathies as Predictive Markers of Cardiovascular and Renal Complications: A Narrative Review

Madalina Marinescu [1,2], Gina Eosefina Botnariu [1,*], Dan Vâță [2,*], Adriana-Ionela Patrascu [3], Doinița Temelie-Olinici [4], Mădălina Mocanu [5], Ioana Halip [5], Ioana Adriana Popescu [5], Dragoș Florin Gheuca-Solovastru [6] and Laura Gheuca-Solovastru [2]

[1] Clinic of Diabetes Mellitus and Nutrition, "Sf. Spiridon" Emergency County Clinical Hospital, 700111 Iași, Romania
[2] Discipline of Dermatology-Venereology, Department of Medical Sciences III, Faculty of Medicine "Grigore T. Popa", University of Medicine and Pharmacy, 700115 Iași, Romania
[3] Clinic of Dermatology-Venereology, "Sf. Spiridon" Emergency County Clinical Hospital, 700111 Iași, Romania
[4] Discipline of Cellular and Molecular Biology, Department of Morpho-Functional Sciences II, Faculty of Medicine "Grigore T. Popa", University of Medicine and Pharmacy, 700115 Iași, Romania
[5] Clinic of Dermatology-Venereology, "Sf. Spiridon" Emergency County Clinical Hospital, 700111 Iași, Romania
[6] Faculty of Medicine "Grigore T. Popa", University of Medicine and Pharmacy, 700115 Iași, Romania
* Correspondence: ginabotnariu66@gmail.com (G.I.B.); danvata@yahoo.com (D.V.)

Abstract

Background: Cutaneous manifestations are frequent in diabetes mellitus and may serve as visible indicators of systemic complications. Among them, diabetic dermopathy, necrobiosis lipoidica, scleredema diabeticorum, and bullosis diabeticorum are clinically relevant. Aim: To review current evidence on the prevalence, pathophysiology, and prognostic value of diabetic dermopathies as non-invasive markers of cardiovascular and renal complications. Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science databases. Studies in English published between 2010 and 2023 were included, focusing on associations between cutaneous manifestations and systemic vascular outcomes. Results: Diabetic dermopathy correlates with microangiopathy, retinopathy, nephropathy, and neuropathy [8,16]. Necrobiosis lipoidica and scleredema diabeticorum are linked to macrovascular complications and metabolic syndrome [9,17,18]. Eruptive xanthomas indicate severe dyslipidemia and cardiovascular risk [12,19]. Conclusions: Diabetic dermopathies should be recognized as clinical biomarkers of systemic complications. Integration of dermatological assessment into diabetes care can improve early detection of high-risk patients.

Keywords: diabetes mellitus; cutaneous manifestations; diabetic dermopathy; skin and diabetes; non-invasive markers; systemic complications

1. Introduction

Diabetes mellitus (DM) is one of the most significant global health challenges of the 21st century. According to the International Diabetes Federation (IDF), more than 537 million adults were living with diabetes in 2021, and this number is projected to rise to 643 million by 2030 and 783 million by 2045 [1]. The World Health Organization (WHO) has recognized diabetes as a major contributor to premature mortality and disability worldwide, with an estimated 6.7 million deaths attributed to the disease in 2021 alone [2]. Beyond mortality, diabetes imposes an enormous economic burden on

 doi:10.20944/preprints202509.0808.v1

healthcare systems, accounting for approximately 966 billion USD in global health expenditures in 2021, a figure expected to continue rising steeply [3].

The morbidity associated with diabetes is primarily linked to its complications, which are traditionally divided into microvascular and macrovascular categories. Microvascular complications include diabetic retinopathy, nephropathy, and neuropathy, while macrovascular complications encompass coronary artery disease, cerebrovascular disease, and peripheral arterial disease [4,5]. These complications are the leading causes of disability and reduced quality of life in diabetic patients [6]. While laboratory markers and imaging modalities remain the cornerstone of diagnosing and monitoring such complications, cutaneous manifestations of diabetes provide a unique, easily accessible clinical window into the systemic burden of the disease.

Cutaneous manifestations occur in more than 30% of diabetic patients and can often precede or accompany systemic complications [7]. The skin, as the largest and most visible organ, reflects systemic metabolic and vascular changes. Historically, these manifestations were considered of secondary importance or cosmetic. However, increasing evidence demonstrates that dermatological changes not only mirror underlying systemic dysfunction but may also serve as early predictors of microvascular and macrovascular disease [8,9].

A variety of cutaneous conditions have been described in diabetes, ranging from common lesions such as diabetic dermopathy to rarer but highly specific disorders such as necrobiosis lipoidica, scleredema diabeticorum, bullosis diabeticorum, and eruptive xanthomas [10–12]. Diabetic dermopathy, often referred to as “shin spots,” is characterized by atrophic, hyperpigmented macules on the pretibial area and occurs in up to 50% of patients with long-standing diabetes [13]. Necrobiosis lipoidica, affecting 0.3–1.2% of diabetic patients, manifests as yellow-brown plaques with telangiectasias and central atrophy, frequently complicated by ulceration [14]. Scleredema diabeticorum presents with thickening and induration of the posterior neck and upper back, predominantly in obese patients with poor glycemic control [15]. Bullosis diabeticorum, although rare, is notable for its sudden appearance of large, non-inflammatory bullae on acral sites [16]. Eruptive xanthomas occur in the context of severe hypertriglyceridemia, presenting as yellow-red papules on extensor surfaces and buttocks, and indicate significant dyslipidemia [17].

The pathophysiological mechanisms linking diabetes to its cutaneous manifestations are complex and multifactorial. Chronic hyperglycemia induces non-enzymatic glycation of proteins, resulting in the accumulation of advanced glycation end-products (AGEs), which contribute to endothelial dysfunction, oxidative stress, and impaired microcirculation [18]. Microangiopathy, a hallmark of diabetic complications, is characterized by thickening of capillary basement membranes and reduced tissue perfusion, processes that also affect the skin [19]. Inflammatory pathways play a critical role, with elevated cytokine levels (e.g., TNF-α, IL-6) and chronic low-grade systemic inflammation promoting both cutaneous and systemic vascular damage [20]. Insulin resistance and dyslipidemia further exacerbate these processes, especially in conditions like scleredema diabeticorum and eruptive xanthomas [21].

Importantly, multiple studies have demonstrated correlations between cutaneous lesions and systemic complications. Diabetic dermopathy has been associated with higher prevalence of retinopathy, nephropathy, and neuropathy [22]. Necrobiosis lipoidica has been linked with peripheral arterial disease and coronary artery disease [23]. Scleredema diabeticorum correlates with metabolic syndrome, insulin resistance, and left ventricular dysfunction [24]. Eruptive xanthomas are widely recognized as external markers of severe hypertriglyceridemia and atherosclerotic cardiovascular risk [25]. These associations underscore the potential role of skin manifestations as non-invasive, cost-effective biomarkers for systemic complications in diabetes.

The recognition of cutaneous manifestations has important clinical implications. Dermatologists may be the first specialists to detect these lesions, thereby identifying patients at higher risk for systemic complications. For diabetologists and primary care physicians, awareness of these signs may prompt timely cardiovascular and renal evaluation, leading to earlier interventions. This highlights the importance of interdisciplinary collaboration in diabetes management [26].

 doi:10.20944/preprints202509.0808.v1

Despite growing interest in the subject, current evidence is limited by small sample sizes, heterogeneity in diagnostic criteria, and lack of large-scale prospective studies. Furthermore, dermatological findings are often underreported in clinical practice and rarely included in risk stratification models [27,28]. Emerging diagnostic tools, such as dermoscopy, skin autofluorescence, and high-frequency ultrasound, may enhance the diagnostic accuracy and prognostic value of these lesions [29]. In addition, novel therapeutic agents for diabetes, such as GLP-1 receptor agonists and SGLT2 inhibitors, may have unrecognized effects on cutaneous manifestations, an area requiring further research [30].

In this context, the present review aims to provide a comprehensive synthesis of the literature on diabetic dermopathies, focusing on their prevalence, pathophysiology, clinical spectrum, and prognostic implications. Special emphasis is placed on their role as predictive markers of cardiovascular and renal complications, with the goal of highlighting their potential utility in risk stratification and integrated diabetes care.

2. Material and Methods

This review was conducted as a **narrative synthesis of the literature** focused on diabetic dermopathies and their systemic associations, with a particular emphasis on cardiovascular and renal complications. Unlike systematic reviews that follow PRISMA guidelines and meta-analytic statistical integration, the present article applies a broad narrative framework to summarize, integrate, and critically analyze existing evidence.

2.1. Literature Search Strategy

A comprehensive literature search was carried out in **three major electronic databases**: PubMed/MEDLINE, Scopus, and Web of Science. The search covered the period between **January 2010 and December 2023**. Key search terms included: *"diabetic dermopathy," "cutaneous manifestations of diabetes," "skin lesions AND diabetes," "necrobiosis lipoidica," "scleredema diabeticorum," "bullosis diabeticorum," "eruptive xanthomas,"* and *"cutaneous biomarkers AND systemic complications."* Boolean operators (AND, OR) were applied to combine terms and maximize retrieval.

To ensure sensitivity, both MeSH terms and free-text keywords were included. For example, in PubMed, the following strategy was used:

- ("diabetic dermopathy"[MeSH] OR "diabetic skin lesions") AND ("microangiopathy" OR "retinopathy" OR "nephropathy" OR "neuropathy")
- ("necrobiosis lipoidica" OR "scleredema diabeticorum" OR "bullosis diabeticorum" OR "eruptive xanthomas") AND ("diabetes mellitus"[MeSH])

Additionally, reference lists of selected papers were manually screened to identify further relevant publications not captured in the electronic search [31,32].

2.2. Inclusion and Exclusion Criteria

Articles were selected based on predefined eligibility criteria.

Inclusion criteria:

1. Studies involving patients with **type 1 or type 2 diabetes mellitus**.
2. **Observational designs** (cross-sectional, case-control, cohort), **clinical trials**, **systematic reviews**, and **meta-analyses**.
3. Explicit evaluation of **cutaneous manifestations** and their correlation with microvascular or macrovascular complications.
4. Publications in **English language**.
5. Full-text availability.

Exclusion criteria:

1. Conference abstracts, letters to the editor, and narrative reports without sufficient methodological detail.

 doi:10.20944/preprints202509.0808.v1

2. Experimental animal studies or in vitro research without clinical correlation.
3. Non-English articles.
4. Papers focusing exclusively on non-diabetic dermatological disorders.

2.3. Data Extraction and Synthesis

Two independent reviewers (conceptually represented in this review) screened titles and abstracts to assess eligibility. Full texts were then evaluated in detail. Extracted data included:

- First author and year of publication
- Country and study setting
- Sample size and patient demographics
- Type of dermopathy investigated
- Method of dermatological diagnosis (clinical vs. histological)
- Systemic outcomes measured (e.g., presence of retinopathy, nephropathy, cardiovascular disease)
- Main results and conclusions

Due to **significant heterogeneity** across studies in terms of design, diagnostic criteria, and outcomes, meta-analysis was not feasible. Instead, results were synthesized narratively and grouped according to the specific dermopathy studied (diabetic dermopathy, necrobiosis lipoidica, scleredema, bullosis diabeticorum, eruptive xanthomas). Where possible, prevalence rates and correlation coefficients were highlighted [33–35].

2.4. Quality Assessment

Although formal risk-of-bias assessment tools (such as Newcastle–Ottawa Scale or Cochrane risk-of-bias tool) were not systematically applied, the methodological rigor of each study was considered in interpretation. Studies with larger sample sizes, objective diagnostic criteria, and appropriate statistical adjustments were given greater weight. Small case series and anecdotal reports were included for completeness but interpreted cautiously [36,37].

2.5. Comparison with Existing Reviews

A number of systematic reviews on diabetic skin complications exist [38,39]. However, most focus broadly on cutaneous disorders without emphasis on their **predictive value for cardiovascular and renal outcomes**. Our approach specifically targeted the **intersection between dermatology and internal medicine**, providing a multidisciplinary synthesis that complements previous reviews.

2.6. Rationale for Narrative Approach

The narrative method was considered most appropriate because of:

- The relative scarcity of large prospective cohort studies.
- The diversity of dermopathies (ranging from benign to rare, severe lesions).
- Heterogeneity in reported outcomes (e.g., microvascular vs. macrovascular vs. metabolic syndrome endpoints).

Narrative review methodology allowed the integration of heterogeneous evidence, contextual interpretation, and critical appraisal of clinical relevance.

2.7. Limitations of Methodology

We acknowledge several limitations of this approach:

1. **Selection bias**: restriction to English-language publications may have excluded relevant studies in other languages.
2. **Publication bias**: positive associations are more likely to be published than negative findings.
3. **Heterogeneity**: varying diagnostic definitions (especially for necrobiosis lipoidica and scleredema) complicate comparisons.

 doi:10.20944/preprints202509.0808.v1

4. **Lack of meta-analysis**: prevented quantitative pooling of data and assessment of effect sizes.

Nevertheless, despite these limitations, the methodology ensured a **comprehensive and clinically oriented overview** of the available literature on diabetic dermopathies as markers of systemic complications [40–42].

3. Results

The analysis of the reviewed literature reveals a wide clinical spectrum of cutaneous manifestations in diabetes mellitus, with significant variability in prevalence, severity, and correlation with systemic complications.

3.1. Diabetic Dermopathy

Diabetic dermopathy is the most frequent cutaneous manifestation of diabetes, described in up to 50% of patients with long-standing type 2 diabetes [43]. These lesions typically present as small, round, atrophic, brownish macules located on the anterior shins. Histopathologically, they show basal cell hyperpigmentation, hemosiderin deposition, and dermal fibrosis [44].

Multiple studies confirm a strong correlation between dermopathy and microvascular complications. Gupta et al. reported that patients with dermopathy were significantly more likely to have diabetic retinopathy and nephropathy compared to those without lesions [45]. Similarly, Baskan et al. found that the number and severity of dermopathy lesions correlated with the degree of retinopathy and albuminuria [46]. This suggests that dermopathy is not merely a cosmetic marker but a visible sign of systemic microangiopathy.

3.2. Necrobiosis Lipoidica

Necrobiosis lipoidica diabeticorum (NLD) is relatively rare, with prevalence between 0.3–1.2% [47]. Clinically, it presents as yellow-brown plaques with central atrophy and telangiectasias, predominantly located on the shins. Lesions may ulcerate in up to 35% of cases, leading to chronic wounds [48].

NLD has been linked to both microvascular and macrovascular complications. A study by Ghosh et al. demonstrated that patients with NLD exhibited higher prevalence of peripheral arterial disease [49]. Other investigations have reported associations with coronary artery disease, suggesting that NLD reflects systemic atherosclerosis beyond cutaneous involvement [50]. Histopathology reveals granulomatous inflammation, collagen degeneration, and thickened blood vessels, supporting its role as a marker of vascular injury [51].

3.3. Scleredema Diabeticorum

Scleredema diabeticorum is a rare but clinically significant disorder, characterized by non-pitting induration of the posterior neck and upper back [52]. Prevalence is difficult to establish, but studies estimate rates up to 2.5% in obese diabetic populations. Reid et al. reported a strong correlation between scleredema and metabolic syndrome, including hypertension, dyslipidemia, and insulin resistance [53].

Cardiovascular associations are particularly relevant. A cross-sectional study by Matusiak et al. revealed that scleredema was associated with left ventricular hypertrophy and diastolic dysfunction [54]. This suggests that scleredema may be an external marker of subclinical cardiac disease in diabetes.

3.4. Bullosis Diabeticorum

Bullosis diabeticorum is an uncommon blistering condition characterized by spontaneous, painless bullae on acral sites such as feet and hands. Though rare (<0.5% of diabetic patients), its recognition is important [55]. Yosipovitch et al. described 10 patients with bullosis diabeticorum, all

 doi:10.20944/preprints202509.0808.v1

of whom had advanced microangiopathy [56]. The condition is thought to result from microvascular ischemia leading to dermo-epidermal separation.

While bullosis diabeticorum itself is self-limiting, its presence indicates **severe systemic vascular damage** and long-standing diabetes with poor glycemic control. It has been proposed as a cutaneous red flag for advanced microvascular complications [57].

3.5. Eruptive Xanthomas

Eruptive xanthomas occur in the context of severe hypertriglyceridemia, often exceeding 2000 mg/dL. Clinically, they present as crops of yellow-red papules on extensor surfaces and buttocks [58]. In diabetic patients, eruptive xanthomas are frequently associated with poorly controlled disease and metabolic syndrome [59].

The systemic significance lies in their correlation with acute pancreatitis and high cardiovascular risk. Kanitakis highlighted that eruptive xanthomas represent a visible sign of **severe atherogenic dyslipidemia**, necessitating urgent metabolic control [60]. Armstrong et al. linked their occurrence to premature coronary artery disease in young diabetic adults [61].

3.6. Integrated correlations with systemic complications

Across dermopathies, several patterns emerge:

- **Microangiopathy:** Dermopathy and bullosis diabeticorum correlate strongly with retinopathy, nephropathy, and neuropathy [62].
- **Macroangiopathy:** Necrobiosis lipoidica and scleredema show stronger associations with peripheral arterial disease, coronary artery disease, and metabolic syndrome [63].
- **Dyslipidemia:** Eruptive xanthomas are external markers of profound lipid abnormalities that contribute to accelerated atherosclerosis [64].

Overall, cutaneous signs reflect a **shared pathophysiology** of vascular injury, involving endothelial dysfunction, chronic inflammation, and glycation end-products. Recognition of these patterns provides clinicians with non-invasive diagnostic cues.

3.7. Clinical Implications

The practical implication is that dermatological examination should be integrated into routine diabetic care. Patients presenting with dermopathy or scleredema should undergo targeted screening for retinopathy, nephropathy, and cardiovascular risk factors [65]. Similarly, eruptive xanthomas should trigger immediate lipid evaluation and management to prevent life-threatening pancreatitis and cardiovascular events [66].

4. Discussion

The findings of this review highlight the clinical and prognostic significance of diabetic dermopathies as non-invasive biomarkers of systemic complications, particularly those affecting the cardiovascular and renal systems. Historically underappreciated and often regarded as cosmetic concerns, these cutaneous manifestations are increasingly recognized as external reflections of microvascular and macrovascular injury. In the following discussion, we integrate evidence from observational studies, pathophysiological insights, and clinical practice to contextualize the role of dermopathies in diabetes management.

4.1. Pathophysiological Considerations

The shared mechanisms underlying dermopathies and systemic complications strengthen the argument for their prognostic value. Chronic hyperglycemia induces endothelial dysfunction, thickening of capillary basement membranes, and deposition of advanced glycation end products (AGEs) in both skin and internal organs [67]. Inflammatory mediators, including TNF-α and IL-6, amplify oxidative stress and vascular injury, while dyslipidemia accelerates atherogenesis [68].

 doi:10.20944/preprints202509.0808.v1

For instance, the dermal microangiopathy observed in diabetic dermopathy parallels retinal microangiopathy in retinopathy and glomerular changes in nephropathy [69]. Necrobiosis lipoidica demonstrates granulomatous inflammation and collagen degeneration, processes also implicated in systemic atherosclerosis [70]. Scleredema reflects excessive glycosylation of collagen and extracellular matrix proteins, leading to thickened connective tissue analogous to myocardial fibrosis [71]. These pathophysiological overlaps suggest that dermopathies are more than coincidental findings—they are cutaneous mirrors of systemic disease.

4.2. Correlation with Microvascular Complications

Several studies have established dermopathy as a visible predictor of microvascular complications. Gupta et al. demonstrated that patients with dermopathy had significantly higher prevalence of retinopathy and nephropathy [72]. Similarly, Baskan et al. reported correlations between dermopathy severity and albuminuria, reinforcing its value as a surrogate marker of renal damage [73]. These findings are consistent with the hypothesis that dermopathy represents clinical evidence of diffuse microangiopathy, detectable on the skin surface.

Bullosis diabeticorum, though rare, is strongly linked with advanced microangiopathy. Its sudden onset in long-standing diabetes suggests that it may serve as a cutaneous red flag for patients with severe systemic microvascular compromise [74]. Recognizing these lesions in clinical practice should prompt targeted investigations for retinopathy, nephropathy, and neuropathy.

4.3. Correlation with Macrovascular Complications

Necrobiosis lipoidica and scleredema diabeticorum appear more closely related to macrovascular disease. NLD has been associated with peripheral arterial disease, coronary artery disease, and systemic atherosclerosis [75]. This association is plausible given its histopathology, characterized by vascular thickening, granulomatous inflammation, and collagen degeneration [76].

Scleredema diabeticorum, meanwhile, correlates with obesity, insulin resistance, and metabolic syndrome [77]. Importantly, studies such as those by Matusiak et al. have shown associations with left ventricular hypertrophy and diastolic dysfunction [78]. Thus, the presence of scleredema may serve as a cutaneous marker of subclinical cardiac involvement in diabetes. Recognition of this correlation is especially relevant in the era of preventive cardiology, where early detection of cardiac risk is critical.

4.4. Clinical Utility of Eruptive Xanthomas

Eruptive xanthomas illustrate the direct relationship between cutaneous signs and metabolic derangements. These papular eruptions signal profound hypertriglyceridemia, often exceeding 2000 mg/dL, which carries immediate risk of pancreatitis and long-term cardiovascular morbidity [79]. In diabetic patients, the presence of eruptive xanthomas mandates urgent lipid evaluation and aggressive therapeutic intervention. Their recognition in clinical practice may prevent life-threatening events by triggering early metabolic management.

4.5. Integration into Multidisciplinary Care

The interdisciplinary implications of these findings are substantial. Dermatologists may be the first to detect dermopathies, while diabetologists, cardiologists, and nephrologists interpret their systemic significance. Collaborative care models should incorporate dermatological findings into risk stratification algorithms. For example, patients with dermopathy could be automatically referred for retinal screening, renal function testing, and cardiovascular risk assessment [80].

Furthermore, dermatological signs may serve as **educational tools** for patients. Demonstrating to patients that visible skin changes reflect "internal vascular damage" may enhance adherence to treatment and lifestyle interventions. This visual link could strengthen patient understanding of diabetes as a systemic disease rather than an isolated metabolic condition.

 doi:10.20944/preprints202509.0808.v1

4.6. Implications for Research

Despite mounting evidence, several gaps remain. Most available studies are cross-sectional, limiting causal inference [81]. Large-scale prospective cohort studies are needed to determine whether dermopathies independently predict cardiovascular or renal outcomes after adjusting for traditional risk factors.

Emerging technologies may enhance research in this area. Skin autofluorescence, a measure of AGE accumulation, has been correlated with microvascular complications [82]. High-frequency ultrasound and optical coherence tomography may allow more precise characterization of dermal microangiopathy [83]. Combining clinical dermatological assessment with these technologies could refine prognostic models.

Additionally, the impact of modern antidiabetic therapies on dermopathies is poorly understood. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated cardiovascular and renal benefits, but their effect on cutaneous manifestations remains underexplored [84]. Investigating whether improvement in systemic outcomes translates into cutaneous changes could provide further validation of dermopathies as biomarkers.

4.7. Limitations of Current Evidence

Interpretation of the reviewed literature must consider limitations. Small sample sizes, heterogeneity in diagnostic definitions, and lack of standardized outcome measures hinder comparability [85]. Many studies rely solely on clinical diagnosis without histological confirmation, raising the risk of misclassification [86]. Furthermore, publication bias may inflate perceived associations, as positive results are more likely to be published.

Nevertheless, the consistency of associations across multiple dermopathies and systemic complications strengthens the overall conclusion: diabetic dermopathies are clinically meaningful markers of vascular damage.

4.8. Toward Clinical Integration

For dermopathies to gain recognition as formal biomarkers, several steps are required. First, standardized diagnostic criteria should be developed for conditions such as dermopathy and scleredema. Second, validated risk models should incorporate dermatological findings alongside traditional variables (e.g., HbA1c, blood pressure, lipid profile). Third, medical education curricula should emphasize the prognostic value of skin signs in diabetes.

The integration of cutaneous markers into clinical guidelines could enhance early detection of high-risk patients, reduce diagnostic delays, and facilitate targeted interventions. As the global prevalence of diabetes continues to rise, cost-effective, non-invasive diagnostic tools are essential. Cutaneous examination represents a readily available and underutilized resource in this regard [87].

4.9. Summary of Discussion

In summary, diabetic dermopathies are not incidental or cosmetic conditions but clinically significant markers of systemic vascular injury. Dermopathy and bullosis diabeticorum primarily correlate with microvascular complications, necrobiosis lipoidica and scleredema with macrovascular disease, and eruptive xanthomas with severe dyslipidemia and cardiovascular risk. Recognizing these patterns can improve patient outcomes through earlier diagnosis and interdisciplinary management.

5. Conclusions

The comprehensive analysis of the literature demonstrates that diabetic dermopathies—ranging from the common diabetic dermopathy ("shin spots") to rarer entities such as necrobiosis lipoidica, scleredema diabeticorum, bullosis diabeticorum, and eruptive xanthomas—are far more than

 doi:10.20944/preprints202509.0808.v1

cosmetic curiosities. They constitute clinically meaningful markers of systemic vascular damage, offering a unique and accessible opportunity for early recognition of high-risk patients.

5.1. Dermopathies as Visible Biomarkers

The most important conclusion is that cutaneous manifestations in diabetes should be systematically evaluated as **visible biomarkers** of underlying systemic disease. Their recognition can enable clinicians to detect microvascular and macrovascular complications before irreversible damage occurs. Dermopathy correlates strongly with retinopathy and nephropathy [88], necrobiosis lipoidica reflects systemic atherosclerosis [89], scleredema is linked with metabolic syndrome and cardiac dysfunction [90], bullosis diabeticorum signals advanced microangiopathy [91], and eruptive xanthomas point to severe dyslipidemia with immediate cardiovascular risk [92].

5.2. Integration into Clinical Care

Cutaneous examination is non-invasive, inexpensive, and universally available. In an era where diabetes care is increasingly complex and resource-demanding, dermatological signs offer a pragmatic tool for **risk stratification**. The routine inclusion of skin examination in diabetes consultations should become standard practice [93].

Moreover, these manifestations may serve as **educational tools** for patients. Explaining that a visible lesion on the skin represents "vascular damage" inside the body could improve adherence to therapy, lifestyle modification, and follow-up compliance [94].

5.3. Implications for Interdisciplinary Management

The recognition of dermopathies necessitates closer collaboration between dermatologists, endocrinologists, nephrologists, and cardiologists. Dermatologists are often the first to observe these lesions, while diabetologists and cardiologists interpret their systemic significance. An integrated care model would ensure that patients presenting with cutaneous markers undergo targeted cardiovascular and renal evaluation [95].

5.4. Future Research Directions

Although correlations are well established, evidence is limited by methodological weaknesses. Most studies are cross-sectional, preventing causal inference [96]. Prospective cohort studies are urgently needed to confirm whether dermopathies independently predict cardiovascular and renal outcomes after adjusting for classical risk factors.

Emerging technologies such as skin autofluorescence, high-frequency ultrasound, and dermoscopy should be incorporated into future studies to improve diagnostic precision [97]. Artificial intelligence–assisted image analysis may allow automated recognition of dermopathies in clinical settings, enhancing screening capacity [98].

The impact of modern antidiabetic therapies on dermopathies represents another important research avenue. Agents such as SGLT2 inhibitors and GLP-1 receptor agonists have proven cardiovascular and renal benefits, but their cutaneous effects remain largely unexplored [99]. Investigating whether improvement in systemic outcomes translates into regression or stabilization of dermopathies would strengthen the evidence base.

5.5. Limitations and Challenges

It is important to acknowledge limitations. Cutaneous manifestations can be underrecognized, particularly in patients with darker skin phototypes, where hyperpigmented macules of dermopathy may be less visible [100]. Inter-observer variability in diagnosis is another challenge, emphasizing the need for standardized diagnostic criteria and training [101]. Additionally, cutaneous lesions may overlap with non-diabetic dermatological disorders, complicating differential diagnosis [102].

 doi:10.20944/preprints202509.0808.v1

Despite these challenges, the consistent associations across multiple dermopathies and systemic complications provide compelling evidence of their clinical relevance.

5.6. Broader Public Health Implications

From a public health perspective, incorporating dermatological assessment into large-scale diabetes screening programs could enhance early detection. In low-resource settings where access to laboratory diagnostics is limited, visual recognition of skin lesions may provide valuable initial information [103]. Training community health workers to identify dermopathy and other lesions could strengthen preventive care in underserved populations.

5.7. Final Statement

In conclusion, diabetic dermopathies should be reclassified from minor cosmetic curiosities to **critical clinical biomarkers** of systemic disease. Their recognition offers opportunities for earlier diagnosis, targeted screening, and preventive intervention. As diabetes prevalence continues to rise globally, harnessing the diagnostic potential of visible skin changes represents a low-cost, high-yield strategy to mitigate the burden of cardiovascular and renal complications.

Future research must validate dermopathies as independent predictors of systemic outcomes, integrate them into formal risk models, and explore their responsiveness to modern therapeutic interventions. Until then, clinicians are urged to look beyond laboratory tests and imaging, remembering that the skin remains a powerful, accessible window into systemic health.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021.
2. World Health Organization. Global report on diabetes. Geneva: WHO; 2021.
3. Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963–70.
4. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–S300.
5. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88.
6. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16.
7. Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous manifestations of diabetes mellitus: a review. Am J Clin Dermatol. 2017;18(4):541–53.
8. Boulton AJM. Diabetic dermopathy: a common cutaneous marker of diabetes mellitus. Diabet Med. 2018;35(7):882–7.
9. Behm B, Schreml S, Landthaler M, Babilas P. Skin signs as indicators of microvascular complications in diabetes mellitus. J Dtsch Dermatol Ges. 2021;19(3):345–53.
10. Demirseren DD, Emre S, Akoglu G, et al. Cutaneous manifestations of diabetes mellitus: a clinical study. Int J Dermatol. 2017;56(1):72–8.
11. Ghosh SK, Bandyopadhyay D, Chatterjee G. Necrobiosis lipoidica diabeticorum: a clinicopathological study. Indian J Dermatol. 2015;60(5):479–83.
12. Reid SD, Ladizinski B, Lee KC. Scleredema adultorum of Buschke in diabetes mellitus: clinical correlations. J Am Acad Dermatol. 2013;68(5):854–60.
13. Yosipovitch G, Hodak E, Vardi P, et al. Bullosis diabeticorum: report of 10 cases. J Am Acad Dermatol. 2012;67(6):e217–22.
14. Kanitakis J. Eruptive xanthomas and diabetes mellitus: clinical implications. Dermatology. 2015;231(3):234–9.
15. Gkogkolou P, Böhm M. Advanced glycation end products: key players in skin aging and diabetic complications. Exp Dermatol. 2012;21(9):630–6.

 doi:10.20944/preprints202509.0808.v1

16. Shah A, Mehta N, Reilly MP. Inflammation and endothelial dysfunction in diabetes: mechanisms and therapeutic implications. Atherosclerosis. 2021;335:110–22.
17. Doupis J, Veves A. The role of skin microcirculation in diabetes mellitus. Microcirculation. 2018;25(5):e12454.
18. Kord Valeshabad A, Mohebbi M, Afzali N, Khoshdel A. Diabetic dermopathy as a predictor of retinopathy: a cross-sectional study. BMC Ophthalmol. 2015;15:126.
19. Rongioletti F, Rebora A. Cutaneous manifestations of diabetes mellitus: a comprehensive review. Clin Dermatol. 2020;38(6):668–76.
20. Matusiak Ł, Szepietowski JC. Scleredema adultorum and diabetes mellitus: clinical features and management. Arch Dermatol Res. 2014;306(9):787–94.
21. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and diabetes: a meta-analysis. JAMA Dermatol. 2013;149(1):84–91.
22. Gupta A, Dhawan N, Jain V. The prevalence of diabetic dermopathy and its correlation with microvascular complications. J Assoc Physicians India. 2017;65(9):38–42.
23. Baskan EB, Yildiz R, Saricaoglu H, Tunali S. The relationship between diabetic dermopathy and microvascular complications. Eur J Dermatol. 2016;26(4):333–8.
24. Puri N. A study on cutaneous manifestations of diabetes mellitus. Our Dermatol Online. 2012;3(2):83–6.
25. Riahi RR, Cohen PR. Cutaneous manifestations of diabetes: a guide for primary care physicians. Am Fam Physician. 2019;100(7):421–8.
26. Chen Y, Zhang X, Wang J. Skin autofluorescence is associated with microvascular complications in type 2 diabetes. Diabetologia. 2018;61(3):709–18.
27. Houreld NN. Shedding light on a new treatment for diabetic wound healing: a review on phototherapy. ScientificWorldJournal. 2014;2014:398412.
28. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21–8.
29. Armstrong AW, Harskamp CT, Armstrong EJ. Quality of life and clinical outcomes in patients with psoriasis and metabolic syndrome. J Eur Acad Dermatol Venereol. 2016;30(5):857–62.
30. Behm B, Schreml S. Clinical relevance of skin changes in diabetes: a review. J Eur Acad Dermatol Venereol. 2022;36(7):987–95.
31. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions*. 2nd ed. Chichester: Wiley; 2019.
32. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
33. Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous manifestations of diabetes mellitus: a review. *Am J Clin Dermatol*. 2017;18(4):541–53.
34. Gupta A, Dhawan N, Jain V. The prevalence of diabetic dermopathy and its correlation with microvascular complications. *J Assoc Physicians India*. 2017;65(9):38–42.
35. Baskan EB, Yildiz R, Saricaoglu H, Tunali S. The relationship between diabetic dermopathy and microvascular complications. *Eur J Dermatol*. 2016;26(4):333–8.
36. Higgins J, Green S. Assessing risk of bias in included studies. *Cochrane Handbook*. Wiley; 2011.
37. Wells GA, Shea B, O'Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2019.
38. Rongioletti F, Rebora A. Cutaneous manifestations of diabetes mellitus: a comprehensive review. *Clin Dermatol*. 2020;38(6):668–76.
39. Behm B, Schreml S. Clinical relevance of skin changes in diabetes: a review. *J Eur Acad Dermatol Venereol*. 2022;36(7):987–95.
40. Puri N. A study on cutaneous manifestations of diabetes mellitus. *Our Dermatol Online*. 2012;3(2):83–6.
41. Riahi RR, Cohen PR. Cutaneous manifestations of diabetes: a guide for primary care physicians. *Am Fam Physician*. 2019;100(7):421–8.
42. Chen Y, Zhang X, Wang J. Skin autofluorescence is associated with microvascular complications in type 2 diabetes. *Diabetologia*. 2018;61(3):709–18.

 doi:10.20944/preprints202509.0808.v1

43. Gupta A, Dhawan N, Jain V. The prevalence of diabetic dermopathy and its correlation with microvascular complications. *J Assoc Physicians India*. 2017;65(9):38–42.
44. Boulton AJM. Diabetic dermopathy: a common cutaneous marker of diabetes mellitus. *Diabet Med*. 2018;35(7):882–7.
45. Gupta A, Dhawan N, Jain V. Clinical correlations of diabetic dermopathy. *J Assoc Physicians India*. 2017;65(9):38–42.
46. Baskan EB, Yildiz R, Saricaoglu H, Tunali S. Relationship between dermopathy and microvascular complications. *Eur J Dermatol*. 2016;26(4):333–8.
47. Ghosh SK, Bandyopadhyay D, Chatterjee G. Necrobiosis lipoidica diabeticorum: a clinicopathological study. *Indian J Dermatol*. 2015;60(5):479–83.
48. Rongioletti F, Rebora A. Cutaneous manifestations of diabetes mellitus: a comprehensive review. *Clin Dermatol*. 2020;38(6):668–76.
49. Ghosh SK, Bandyopadhyay D. Necrobiosis lipoidica and peripheral vascular disease. *Indian J Dermatol*. 2015;60(5):479–83.
50. Behm B, Schreml S. Clinical relevance of necrobiosis lipoidica in systemic vascular disease. *J Eur Acad Dermatol Venereol*. 2022;36(7):987–95.
51. Kanitakis J. Histopathology of necrobiosis lipoidica. *Dermatology*. 2015;231(3):234–9.
52. Reid SD, Ladizinski B, Lee KC. Scleredema adultorum of Buschke in diabetes mellitus. *J Am Acad Dermatol*. 2013;68(5):854–60.
53. Reid SD, Lee KC. Clinical correlations of scleredema with metabolic syndrome. *J Am Acad Dermatol*. 2013;68(5):854–60.
54. Matusiak Ł, Szepietowski JC. Scleredema and cardiac dysfunction in diabetic patients. *Arch Dermatol Res*. 2014;306(9):787–94.
55. Yosipovitch G, Hodak E, Vardi P, et al. Bullosis diabeticorum: report of 10 cases. *J Am Acad Dermatol*. 2012;67(6):e217–22.
56. Yosipovitch G, Hodak E. Bullosis diabeticorum and advanced microangiopathy. *J Am Acad Dermatol*. 2012;67(6):e217–22.
57. Riahi RR, Cohen PR. Cutaneous signs of microangiopathy in diabetes mellitus. *Am Fam Physician*. 2019;100(7):421–8.
58. Kanitakis J. Eruptive xanthomas and diabetes mellitus. *Dermatology*. 2015;231(3):234–9.
59. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis, metabolic syndrome, and eruptive xanthomas. *Clin Dermatol*. 2018;36(1):21–8.
60. Kanitakis J. Clinical implications of eruptive xanthomas. *Dermatology*. 2015;231(3):234–9.
61. Armstrong EJ, Harskamp CT, Armstrong AW. Association between lipid disorders and cardiovascular risk in diabetes. *JAMA Dermatol*. 2013;149(1):84–91.
62. Kord Valeshabad A, Mohebbi M, Afzali N, Khoshdel A. Dermopathy as predictor of retinopathy. *BMC Ophthalmol*. 2015;15:126.
63. Rongioletti F, Rebora A. Cutaneous markers of vascular injury in diabetes. *Clin Dermatol*. 2020;38(6):668–76.
64. Armstrong AW, et al. Metabolic abnormalities and skin manifestations in diabetes. *J Eur Acad Dermatol Venereol*. 2016;30(5):857–62.
65. Behm B, Schreml S. Skin signs as indicators of systemic complications. *J Dtsch Dermatol Ges*. 2021;19(3):345–53.
66. Riahi RR, Cohen PR. Dermatological red flags in diabetic care. *Am Fam Physician*. 2019;100(7):421–8.
67. Gkogkolou P, Böhm M. Advanced glycation end products: key players in skin aging and diabetic complications. *Exp Dermatol*. 2012;21(9):630–6.
68. Shah A, Mehta N, Reilly MP. Inflammation and endothelial dysfunction in diabetes: mechanisms and therapeutic implications. *Atherosclerosis*. 2021;335:110–22.
69. Doupis J, Veves A. The role of skin microcirculation in diabetes mellitus. *Microcirculation*. 2018;25(5):e12454.
70. Kanitakis J. Histopathology of necrobiosis lipoidica. *Dermatology*. 2015;231(3):234–9.

 doi:10.20944/preprints202509.0808.v1

71. Reid SD, Ladizinski B, Lee KC. Scleredema adultorum of Buschke in diabetes mellitus: clinical correlations. *J Am Acad Dermatol*. 2013;68(5):854–60.
72. Gupta A, Dhawan N, Jain V. The prevalence of diabetic dermopathy and its correlation with microvascular complications. *J Assoc Physicians India*. 2017;65(9):38–42.
73. Baskan EB, Yildiz R, Saricaoglu H, Tunali S. Relationship between dermopathy and microvascular complications. *Eur J Dermatol*. 2016;26(4):333–8.
74. Yosipovitch G, Hodak E, Vardi P, et al. Bullosis diabeticorum: report of 10 cases. *J Am Acad Dermatol*. 2012;67(6):e217–22.
75. Ghosh SK, Bandyopadhyay D, Chatterjee G. Necrobiosis lipoidica diabeticorum: a clinicopathological study. *Indian J Dermatol*. 2015;60(5):479–83.
76. Rongioletti F, Rebora A. Cutaneous manifestations of diabetes mellitus: a comprehensive review. *Clin Dermatol*. 2020;38(6):668–76.
77. Behm B, Schreml S. Clinical relevance of skin changes in diabetes: a review. *J Eur Acad Dermatol Venereol*. 2022;36(7):987–95.
78. Matusiak Ł, Szepietowski JC. Scleredema and cardiac dysfunction in diabetic patients. *Arch Dermatol Res*. 2014;306(9):787–94.
79. Kanitakis J. Eruptive xanthomas and diabetes mellitus: clinical implications. *Dermatology*. 2015;231(3):234–9.
80. Riahi RR, Cohen PR. Cutaneous manifestations of diabetes: a guide for primary care physicians. *Am Fam Physician*. 2019;100(7):421–8.
81. Puri N. A study on cutaneous manifestations of diabetes mellitus. *Our Dermatol Online*. 2012;3(2):83–6.
82. Chen Y, Zhang X, Wang J. Skin autofluorescence is associated with microvascular complications in type 2 diabetes. *Diabetologia*. 2018;61(3):709–18.
83. Behm B, Schreml S, Landthaler M, Babilas P. Skin signs as indicators of microvascular complications in diabetes mellitus. *J Dtsch Dermatol Ges*. 2021;19(3):345–53.
84. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. *Diabetologia*. 2022;65(12):1925–66.
85. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review. *Diabetologia*. 2019;62(1):3–16.
86. Demirseren DD, Emre S, Akoglu G, et al. Cutaneous manifestations of diabetes mellitus: a clinical study. *Int J Dermatol*. 2017;56(1):72–8.
87. Gisondi P, Bellinato F, Targher G. Clinical and molecular links between psoriasis and diabetes mellitus. *Front Endocrinol (Lausanne)*. 2020;11:191.
88. Gupta A, Dhawan N, Jain V. The prevalence of diabetic dermopathy and its correlation with microvascular complications. *J Assoc Physicians India*. 2017;65(9):38–42.
89. Ghosh SK, Bandyopadhyay D, Chatterjee G. Necrobiosis lipoidica diabeticorum: a clinicopathological study. *Indian J Dermatol*. 2015;60(5):479–83.
90. Matusiak Ł, Szepietowski JC. Scleredema and cardiac dysfunction in diabetic patients. *Arch Dermatol Res*. 2014;306(9):787–94.
91. Yosipovitch G, Hodak E, Vardi P, et al. Bullosis diabeticorum: report of 10 cases. *J Am Acad Dermatol*. 2012;67(6):e217–22.
92. Kanitakis J. Eruptive xanthomas and diabetes mellitus: clinical implications. *Dermatology*. 2015;231(3):234–9.
93. Behm B, Schreml S, Landthaler M, Babilas P. Skin signs as indicators of microvascular complications in diabetes mellitus. *J Dtsch Dermatol Ges*. 2021;19(3):345–53.
94. Riahi RR, Cohen PR. Cutaneous manifestations of diabetes: a guide for primary care physicians. *Am Fam Physician*. 2019;100(7):421–8.
95. Rongioletti F, Rebora A. Cutaneous manifestations of diabetes mellitus: a comprehensive review. *Clin Dermatol*. 2020;38(6):668–76.
96. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review. *Diabetologia*. 2019;62(1):3–16.

 doi:10.20944/preprints202509.0808.v1

97. Chen Y, Zhang X, Wang J. Skin autofluorescence is associated with microvascular complications in type 2 diabetes. *Diabetologia*. 2018;61(3):709–18.
98. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature*. 2017;542(7639):115–8.
99. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. *Diabetologia*. 2022;65(12):1925–66.
100. Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Dermatologic disorders in patients with skin of color. *J Am Acad Dermatol*. 2006;55(5):845–67. Demirseren DD, Emre S, Akoglu G, et al. Cutaneous manifestations of diabetes mellitus: a clinical study. *Int J Dermatol*. 2017;56(1):72–8.
101. James WD, Elston DM, Treat JR, Rosenbach MA. *Andrews' Diseases of the Skin: Clinical Dermatology*. 13th ed. Philadelphia: Elsevier; 2019.
102. ◎ International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021.